Steven C. Katz, MD

Associate Professor, Surgery

Steven Katz
401.456.2000

Other Positions

  • Member, BU-BMC Cancer Center, Boston University
  • Roger Williams Medical Center

Education

  • New York University School of Medicine, MD
  • Wesleyan University, BA

Publications

  • Published on 3/5/2024

    Cook K, Gupta D, Liu Y, Miller-Rosales C, Wei F, Tuttle E, Katz SC, Marshak R, Kim AY. Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases. Curr Med Res Opin. 2024 Mar 05; 1-8. PMID: 38414420.

    Read at: PubMed
  • Published on 6/28/2023

    Capacio BA, Shankara Narayanan JS, Vicente DA, Liu Y, LaPorte JP, Cox BF, Jaroch DB, Katz SC, White RR. Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model. Surgery. 2023 Sep; 174(3):666-673. PMID: 37391328.

    Read at: PubMed
  • Published on 12/1/2022

    Patel SP, Katz SC. Novel treatment paradigms for metastatic uveal melanoma. Cancer Gene Ther. 2022 Dec; 29(12):1807-1808. PMID: 36456705.

    Read at: PubMed
  • Published on 6/15/2022

    Sullivan KM, Jiang X, Guha P, Lausted C, Carter JA, Hsu C, Labadie KP, Kohli K, Kenerson HL, Daniel SK, Yan X, Meng C, Abbasi A, Chan M, Seo YD, Park JO, Crispe IN, Yeung RS, Kim TS, Gujral TS, Tian Q, Katz SC, Pillarisetty VG. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut. 2023 Feb; 72(2):325-337. PMID: 35705369.

    Read at: PubMed
  • Published on 6/14/2022

    Ghosh CC, Heatherton KR, Connell KPO, Alexander IS, Greer DA, LaPorte J, Guha P, Cox BF, Katz SC. Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition. Cancer Gene Ther. 2022 Dec; 29(12):1854-1865. PMID: 35697801.

    Read at: PubMed
  • Published on 3/11/2022

    Guha P, Heatherton KR, O'Connell KP, Alexander IS, Katz SC. Assessing the Future of Solid Tumor Immunotherapy. Biomedicines. 2022 Mar 11; 10(3). PMID: 35327456.

    Read at: PubMed
  • Published on 12/17/2021

    Chai LF, Hardaway JC, Heatherton KR, O'Connell KP, LaPorte JP, Guha P, Lopes MC, Rabinowitz BA, Jaroch D, Cox BF, Knight R, Katz SC. Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model. J Surg Res. 2022 04; 272:37-50. PMID: 34929499.

    Read at: PubMed
  • Published on 12/13/2021

    Guha P, Katz SC. Strategies for manufacturing cell therapy products aligned with patient needs. Methods Cell Biol. 2022; 167:203-226. PMID: 35152997.

    Read at: PubMed
  • Published on 9/4/2021

    DaSilva NA, Barlock BJ, Guha P, Ghosh CC, Trebino CE, Camberg JL, Katz SC, Rowley DC. Proteomic signatures of myeloid derived suppressor cells from liver and lung metastases reveal functional divergence and potential therapeutic targets. Cell Death Discov. 2021 Sep 04; 7(1):232. PMID: 34482371.

    Read at: PubMed
  • Published on 7/21/2021

    Chai LF, Hardaway JC, Heatherton KR, O'Connell KP, Lopes MC, Rabinowitz BA, Ghosh CC, Guha P, Jaroch D, Cox BF, Katz SC. Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. Vaccines (Basel). 2021 Jul 21; 9(8). PMID: 34451932.

    Read at: PubMed

View 73 more publications: View full profile at BUMC

View all profiles